UNI MEDICAL (02666) reported a year-on-year decline of approximately 5.8% in consolidated revenue for the first three quarters.

UNI MEDICAL (02666) announced that in the first three quarters of 2026, amid multiple pressures, the Group maintained strategic focus, deepened the transformation of its financial business, steadily improved its medical service capabilities, and achieved steady progress and quality improvement in overall operations. For the nine months ended September 30, 2026, the Group's consolidated revenue decreased by approximately 5.8% year-on-year, mainly due to the transformation of its financial business; profit for the period increased by approximately 0.2% year-on-year, mainly benefiting from optimized overall funding cost control and a decline in costs related to the medical business; profit for the period attributable to ordinary shareholders increased by approximately 1.2% year-on-year. In the comprehensive medical business, the Group actively responded to medical insurance payment reforms, continued to strengthen development under the "integrated, differentiated, professional, intelligent, and lean" approach, and continuously advanced capacity building in areas such as "discipline development, scientific research and innovation, talent cultivation, and environmental and service improvement." The Group's medical institutions achieved steady progress in overall operations in the first three quarters of 2026: positive results were achieved in discipline capacity building, with 4 new provincial-level key specialties added for a total of 26, and 5 new municipal-level key specialties added for a total of 117; vigorous efforts were made to develop outpatient therapeutic programs and non-medical-insurance businesses, with in-depth implementation of holiday outpatient services, extended-hours outpatient services, and expert outpatient services, achieving 7.477 million outpatient and emergency visits, up 7.5% year-on-year, while outpatient therapeutic revenue increased 3.5% year-on-year; surgical special initiatives were solidly advanced, the surgical mix continued to optimize, and the proportion of Grade III and IV surgeries increased by 2.4 percentage points; standardized diagnosis and treatment by disease type were deepened, the business mix continued to improve, and the proportion of effective revenue increased by 2.3 percentage points year-on-year, steadily enhancing the medical institutions' risk resistance and sustainable development capabilities. In specialty medical care and health technology, the Group advanced through a "dual-wheel" approach of organic development and external expansion to cultivate distinctive businesses and core capabilities. Currently, this segment has made progressive achievements in layout expansion and capacity building. Among them, its subsidiary Universal UNI MEDICAL Technical Services (Tianjin) Co., Ltd. ("Universal Technical Services"), leveraging years of deep practical experience, became a member of the editorial committee of the "Medical Device Blue Book: China Medical Device Industry Development Report (2026)"; its management case "Innovative Practices and Measures for Full-Cycle Management of Medical Equipment Assets" was successfully selected for the practice section of the Blue Book, further enhancing its industry influence. Its subsidiary Universal Universal Qingniao Health Technology Co., Ltd. (Universal Qingniao) in the first three quarters of 2026 added 6 new offline medical-care integrated institutions, with a net increase of 746 nursing-type beds to 4,257 beds, and added 1,880 new home-based elderly care beds under construction and operation to 75,009 beds, continuously expanding its business layout. In addition, the Group continued to advance its health digital intelligence technology business. Its digital intelligence project "Smart Hospital Platform Construction Based on Full-Scenario, Full-Process AI Empowerment" won first prize in the ICT China (2026) Case Selection hosted by the China Communications Enterprises Association, creating a replicable and promotable practical model for the digital transformation of central enterprise hospitals. In the financial business, the Group continued to focus on areas such as medical care and elderly care, equipment manufacturing, chemical and pharmaceutical, and distinctive industries, solidly advanced the planning and implementation of financial business transformation and upgrading, and actively explored new models of industry-finance integration such as "leasing + full-cycle equipment management," "leasing + elderly care operations," "leasing + supply chain finance," and "leasing + technology introduction + operations," serving the modern industrial system and the core responsibilities of central enterprises through financial strength. In the first three quarters of 2026, investment in industrial projects such as equipment manufacturing and chemical and pharmaceutical grew significantly, with the proportion of investment serving core businesses rising from 12.8% in the same period last year to 44.0%, marking a clear improvement in investment structure. As of September 30, 2026, the Group's total interest-earning assets declined slightly compared with the beginning of 2026, net interest margin and net interest spread remained stable compared with the same period last year, overall asset quality remained stable and controllable, and provision coverage remained prudent.